DelveInsight Business Research highlights Karyopharm’s significant milestone — the completion of patient enrollment in its Phase 3 SENTRY trial for myelofibrosis on September 10, 2025. This pivotal advancement marks an important step in expanding treatment options for myelofibrosis patients. Topline data expected soon could reshape the therapeutic landscape for this rare chronic...